BMS-265246

SKU: orb1305177

Description

BMS-265246 is a selective small molecule inhibitor targeting cyclin-dependent kinases 1 and 2 (CDK1/2). It has been utilized in biochemical and cellular assays to study cell cycle progression and has shown antitumor activity in preclinical in vivo cancer models.

Research Area

Cell Biology, Metabolism Research

Key Properties

• CAS Number: 582315-72-8
• MW: 345.34
• Purity: 99.57% (May vary between batches)
• Formula: C₁₈H₁₇F₂N₃O₂
• SMILES: CCCCOc1c(cnc2[nH]ncc12)C(=O)c1c(F)cc(C)cc1F
• Target: Angiotensin-converting Enzyme (ACE),CDK
• Solubility: Ethanol:< 1 mg/mL (insoluble or slightly soluble);10% DMSO+90% Corn Oil:1 mg/mL (2.9 mM);H2O:< 1 mg/mL (insoluble or slightly soluble);DMSO:13.33 mg/mL (38.6 mM)

Bioactivity

• Target IC50:
  CDK1-CyclinB:6 nM|CDK2-CyclinE:9 nM|CDK4-CyclinD:230 nM
• Cell Research:
  HCT-116 cells are plated onto 96-well dishes. For each well, the cell density is calculated by counting the number of objects (cells) per field of view, and averaging across all fields for a given well. For a treatment compound, cell density is converted to a percentage relative to the plate-averaged cell density from DMSO treatment (i.e., 100% corresponds to the average cell density for DMSO treatment). Logistic regression curve fits are done using TIBCO Spotfire, and the concentration at which the curve crosses 50% is reported as the EC50 of BMS-265246.(Only for Reference)

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Cyclin dependent kinase, COVID-19, CHI3L1, CDK1/CyclinB, CDK4/CyclinD, CDK2/CyclinE, CDK, A2780, Calu-3 cells, BMS265246, BMS-265246, BMS 265246, Angiotensin-converting Enzyme (ACE), MCF7 cells, inhibit, Inhibitor, iTreg cell, ovarian cancer, Pyrazolopyridine

Compound Identifiers

PubChem CID

5329775